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Introduction
Epstein-Barr virus (EBV) is a lymphotropic virus 
that is a member of one of the greatest virus families the 
Herpesviridae, and categorize in the gamma herpes virus 
genus. It has a linear, double-stranded DNA genome by 
approximately 170-kilobases in length. It was discovered 
and introduced by Epstein et al., (1964) from a Burkitt 
lymphoma cell line for first time. Also, EBV was the 
first human virus presumed to be oncogenic (Virus et al., 
1997). Investigations estimated that about 90% of the 
adult population worldwide is infected by this virus. In 
developing regions, primary infection by EBV mostly 
occurs in a few years after birth which it is asymptomatic. 
While this primary infection occurs in adolescence or 
adults it can cause self-limiting infectious mononucleosis 
syndrome (Williams and Crawford, 2006). Viral infection 
occurs through saliva which it leads to productive 
oropharyngeal infection. For maintaining lifelong 
persistence infection, latent infection in circulating B 
cells triggered by episomal forms of the viral genome in 
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B cells nuclei (Gandhi et al., 2004; Küppers, 2003; Young 
and Rickinson, 2004). EBV latency is accompanied by 
the low transcription of its nuclear antigens (EBNA), 
latent membrane proteins, small noncoding RNAs, and 
BamHI-A transcripts (Ambinder and Weiss, 1999). EBV 
can run latency in different strategies depends on the 
differentiation of B cells. These strategies cause higher 
survival of EBV-infected cells and viral immune evasions 
from adaptive immune responses (Chen et al., 2006; Rezk 
and Weiss, 2007; Thorley-Lawson, 2001). 
EBV infection is associated with a wide range 
of malignant and non-malignant diseases. It has 
been linked to many human neoplasms, for instance, 
Hodgkin lymphoma (HL), Burkitt lymphoma (BL), 
lymphoproliferative disorders in immunocompromised 
individuals (PTLD), nasopharyngeal carcinoma, gastric 
carcinomas, inflammatory pseudo-tumors of the liver and 
spleen, HIV-associated smooth muscle neoplasms, and 
EBV-associated lymphoproliferative disorders (Arber et 
al., 1995; Iezzoni et al., 1995; Lee et al., 1995; Rezk and 
Weiss, 2007; Yamamoto et al., 1994).
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Studies indicated that EBV genetic variants and 
geographical regions could have a key role in EBV-
associated diseases, but the exact relation is still on debate. 
By considering nuclear antigen sequences (EBNA-2, 
-3A, -3B, and -3C), EBV can divide in type I and II 
(Adldinger et al., 1985; Sample et al., 1990). Although, 
studies on Iranian HL and NHL patients showed the 
EBV and other herpesviruses such as Kaposi’s sarcoma-
associated herpesvirus (KSHV) frequency; there were 
some controversies in the association of EBV infection 
and its genotypes in these patients (Hesamizadeh et al., 
2016; Keyvani et al., 2017). In this preliminary study in 
Iran, we aimed to detect the presence of EBV genome, 
EBV genotyping and then viral load quantitation based on 
EBNA-2 and EBNA-3C genes via molecular techniques, 
in patients with different hematologic malignancies and 
chronic lymphoproliferative disorders to introduce their 
potential risk factors with exposure to EBV infection.
Materials and Methods
Patient selection
Specimens were obtained from patients with 
hematologic malignancies included HL, non-Hodgkin’s 
lymphoma (NHL), acute lymphoblastic leukemia (ALL), 
chronic lymphocytic leukemia (CLL) that diagnosed 
by sophisticated hemato-oncologist based on clinical 
manifestations and laboratory findings, enrolled into the 
current cross-sectional study. Patients were conducted by 
hospitals affiliated with the Iran University of Medical 
Sciences, Tehran, Iran between Dec 2016 and Feb 2018. 
The inclusion criteria were the positive diagnosis of one 
of the mentioned hematologic malignancies (established 
on clinical evaluation included lymph node biopsy 
and flow cytometry on peripheral blood, bone marrow 
aspirate, and so on) and written informed consent and 
the exclusion criteria includes, patients with other 
hematologic disorders, no established diagnosis patients 
and non-availability of the written informed consent. 
All procedures were reviewed and approved by the 
Committee of Human Studies at the Ethics Committee of 
Iran University of Medical Sciences, Tehran, Iran by the 
record number IR.IUMS.REC.1396.32501.
Sample preparation
Peripheral blood samples were collected as 5 cc from 
each patient into EDTA-containing tubes. Hematological 
parameters [white blood cells (WBCs) count, hemoglobin 
(Hochberg et al., 2016) test and platelet (Plt) count] were 
analyzed by the Sysmex XE-2100 (Sysmex Corporation, 
Kobe, Japan), and the PBMCs were collected from the 
whole blood by standard method under centrifugation 
over a density gradient (Lymphoprep, Oslo, Norway) 
(Hesamizadeh et al., 2016). DNA was extracted from 
the PBMCs pellet by using a high pure viral nucleic acid 
kit (Roche Diagnostics GmbH, Mannheim, Germany) 
according to the manufacturer’s protocol. Evaluation of 
purified nucleic acids was done by NanoDrop ND-1000® 
(Thermo Fisher Scientific Inc., Waltham, MA, USA) 
spectrophotometry. Isolated DNA was kept at -20˚C before 
use. EBV positive cell line was got from the national cell 
bank of Iran (Pasture Institute of Iran, Tehran, Iran) that 
extracted by QIAamp Fast DNA Tissue Kit (QIAGEN, 
Hilden, Germany) according to manufacturer instructions.
EBV detection
A nested-PCR (nPCR) performed for EBV infection 
detection via EBNA-2 gene. The first round forward 
primer 5’-GCG GGT GGA GGG AAA GG-3’ and reverse 
5’-GTC AGC CAA GGG ACG CG-3’and the second 
round forward 5’-AGG CTG CCC ACC CTG AGG AT-3’ 
and reverse 5’-GCC ACC TGG CAG CCC TAA AG-3’ 
were used by 240 and 170 bp amplicon sizes, respectively. 
For positive control we used Raji (EBV+) cell line extract. 
The reaction mix contains 0.2–0.5 µM of template DNA 
or controls, 0.5 mM of dNTP mix (Fermentas GmbH, 
Germany), 0.5 µM of each primers, 1.5 µM MgCl2 
(Fermentas GmbH, Germany), 5 units/µl of Taq DNA 
polymerase (Fermentas GmbH, Germany) and sterilized 
DW added to round out the total volume to 25 µl for 
each reaction. A Bio-Rad thermocycler (T100™ Thermal 
Cycler) was used for heating programs. Thermocycler 
heating protocol was included 5 min at 95oC, 40 cycles 
of the 30s at 95oC, 30s at 56oC (for the first round) and 
60oC (for the second round), 40s at 72oC and one final 
extension step at 72oC for 5 min. For visualization of PCR 
products via UV transilluminator, a gel electrophoresis 
was performed by Tris-Boric Acid-EDTA 1× (TBE) buffer 
system and the 1.5% agarose gel stained by Ethidium 
bromide.
EBV genotyping
A conventional-PCR (cPCR) performed for detection 
of EBV genotypes by EBNA-3C gene. A set of EBNA-3C 
primers was used included forward 5’-CGG AAG AGG 
TGG AAA ACA AA-3’ and reverse 5’-GTG GGG GTC 
GTC ATC ATC TC-3’. This primer set could differ EBV 
type I and II by different PCR product sizes 153 and 246 
bp, respectively. For positive control we used Raji cell line 
extracts. PCR conditions included master mix preparation 
and the heating protocol was as nPCR except 58oC for the 
annealing step. 
Quantitative real-time PCR
A SYBER Green quantitative real-time PCR 
(qRT-PCR) performed for viral load quantitation via 
EBNA-3C specific primers. Reaction mixture contains 
7.5µl SYBR RT-PCR Master Mix (Odense M, Denmark) 
corresponds to 1X concentration in each tube, 0.5 µl of 
each mentioned forward and reverse primers (10 pmol/
µl), 0.2–0.5 μM concentration of each sample or controls, 
distilled water added for the rest of the 15 µl total volume. 
The Rotor-Gene-Q 6000 thermocycler (Corbett, Australia) 
was used for Real-time PCR. The heating program was a 
preheating step 5min at 95oC, 40 cycles of 95oC for the 30s 
and 60oC for 30s. The reaction specificity was achieved by 
melting curve analysis. The melting curve was adjusted 
for 50 to 99oC by 5s Intervals. A standard curve efficiency 
0.95 to 1.05 used by a serial dilution manner of standards. 
Generay Biotechnology (Generay Biotechnology Co, 
Shanghai, China) performed for cloning the primers zone 
into pTZ57R/T plasmid. To improve the accuracy of the 
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features of included patients showed in table 1. Based 
on EBNA-2 nPCR results we found 43% (34/79) EBV 
positive that the majority of them were male (61.8%). 
Figure 1 showed results of some EBV positives round 1 
and 2 nPCR. 
Of the 34 EBV positive strains, 26.5 % (9/34) were 
HL, 38.2% (13/34) were NHL, 26.5% (9/34) ALL, 11.8% 
(4/34) were CLL. Cell blood count (CBC) of WBCs, 
Hb and Plt for each groups showed there were not any 
differences in each group. Details are summarized in 
Table 1. 
EBV genotyping (based on different amplicon sizes) 
by EBNA-3C specific primers showed the majority of 
EBV positive strains were genotype I (91.2%) and 8.8% 
(3/34) were genotype II. Figure 2 showed some cPCR for 
analysis, standards were duplicated. 
Statistical analysis
For the statistical analyses in this study we used 
the SPSS version 22 software (SPSS Inc., Chicago, IL, 
USA). Based on the variables we assessed the statistically 
significant with the Chi-square and Mann–Whitney 
U test. The statistically significant were considered as 
p-value<0.05.
Results
From a total of 79 included patients by the mean age 
(y) ± std. deviation 57.7±18.8, 44 (55.7%) were male. 
Included patients were composed of 19 HL, 28 NHL, 











Total n=79 mean age£ ± SD¥ 54.0±18.5 59.3±18.8 53.7±17.9 63.5±18.8 57.7±18.8
Male No. (%) 13 (65) 14 (48.2) 11 (61) 6 (50) 44 (55.7)
mean age ± SD 58.1±15.1 59.0±16.8 54.2±20.0 56.8±28.6 57.5±18.3
Female No. (%) 7 (35) 15 (51.7) 7 (39) 6 (50) 35 (44.3)
mean age ± SD 45.0±23.2 60.2±21.7 56.7±17.7 69.1±6.4 58.0±19.6
Hbȵ 11.2±1.2 11.1±1.1 10.9±1.3 11.0±1.3 11.1±1.2
WBC∞ 13.7±2.8 14.1±3.1 13.9±3.1 13.5±3.0 13.9±3.0
Pltπ 213.1±21.8 216.5±24.3 207.2±30.7 213.3±26.3 236.1±210.4
EBV Positive
n=34 (43%)
No. (%) 8 (40.0) 13 (44.8) 8 (44.4) 52.4±21.1 5 (41.6) 34 (43.0)
mean age ± SD 61.1±14.7 59.8±22.5 59.7±33.6 57.8±21.1
Male No. (%) 7 (87.5) 5 (38.5) 6 (75) 3 (60) 21 (61.8)
mean age ± SD 64.5±11.4 65.8±12.1 51.8±24.0 45.0±49.4 58.4±20.2
Female No. (%) 1 (12.5) 8 (61.5) 2 (25) 2 (40) 13 (38.2)
mean age ± SD 34 56.1±27.2 54.5±9.1 74.5±9.1 57.0±23.3
Hb 10.6±1.5 10.7±1.1 10.9±1.5 10.2±0.8 10.7±1.2
WBC 13.3±3.1 14.8±3.3 12.9±2.8 10.9±0.7 13.4±3.1
Plt 223±25.0 215±27.9 204±42.4 192±11.2 212±30.8
Viral load€ mean ± SD 2.88e5 ± 8.391e5 5.15e5 ± 1.835e6 2781 ± 2.885e3 6.38e5 ± 1.259e6 2.75e5 ± 1.202e6
Range 577 - 2526043 280 - 6622998 280 - 9750 1740 – 2526043 280 - 6622998
EBV Genotype I/II 6/2 12/1 8/0 5/0 31/3
£, years; ¥, Standard deviation; ȵ,, Haemoglobin (g/dL); ∞, white blood cell (103/µL); π, platelet (103/µL); €, copy per μg DNA
Table 1. Demographic Characteristics of Patients with Lymphoproliferative Disorders (N=79)
Figure 1. EBNA-2 nPCR for Detection of EBV 
Infection. Top, first round (product length 240 bp) and 
bottom, second round (product length 170 bp) of nPCR. 
C-, NTC; C+, Raji (EBV+) cell line extract. 
Figure 2. EBV Genotyping by EBNA-3C Specific 
Primers. EBV genotype 1 and 2 have a 153 and 246 bp 
band sizes, respectively. No 8 and 26 are genotype 2 and 
others are genotype 1. No 2, 3, 4, 14, 17 were negative 
or has non-specific bands. C-: NTC; C+: Raji (EBV+) 
cell line extract. 
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EBNA-3C gene results. 66.7% (2/3) EBV-II were found 
in HL and 33.3% (1/3) was in NHL patients. 
A qRT-PCR performed for viral load quantitation 
via serial dilution manner of the cloned standard into 
pTZ57R/T plasmid. After evaluation of primers specificity 
by melting curve analysis, a standard curve (E=1.06) 
used for EBV positive strains analysis. The mean ± std. 
Deviation of viral loads were 2.75×105 ± 1.202×106 
copies/μg DNA that the higher viral load was in NHL 
patients but the results could not shows any statistical 
significance  difference between the groups (p>0.05). 
Details are summarized in Table1.
Statistically, there were not any significant differences 
between EBV infectivity and the four groups of 
lymphoproliferative diseases and chronic blood disorders. 
Statistics showed there were not any significant 
association between age (p=0.1), gender (p=0.3), and EBV 
positivity. Analysis of different variables (age, gender, 
WBC, Hb and Plt) in each four groups (HL, NHL, ALL, 
CLL) with EBV positivity, genotype and viral load had 
not any significant result (p>0.05). Regardless of statistic 
relations, this data has shown that there was no type two 
EBV in ALL and CLL patients. Also, the majority of EBV 
positivity was seen in NHL although more EBV type 2 
was seen in HL patients. 
Discussion
EBV as an oncogenic virus could be presence in 
different stages of B-cell maturation, and could infect 
certain epithelial cells. EBV pathogenic consequences 
could establish various lymphomas and carcinomas that 
its presence in the malignant cells could use for specific 
viral therapy in addition to cancer therapy (Pattle and 
Farrell, 2006).
In the present study, we aimed to find an association 
between EBV infection and hematologic malignancies 
as a preliminary molecular study in Iranian population. 
The probable roles of the viruses in development and 
pathogenesis of EBV in lymphoproliferative disorders and 
hematologic malignancies were quietly studied (Haque 
et al., 2002; Heslop, 2005; Park et al., 2007; Uner et 
al., 2011; Weiss et al., 1991; Weiss et al., 1987). In the 
present study, patients with hematologic malignancies 
were analyzed for EBV infection. Among 79 patients 
which grouped into HL, NHL, ALL and, CLL groups, 
EBV infection detected 40% (8/20), 44.8% (13/29), 
44.4% (8/18), and 41.7% (5/12), respectively (p-values 
were not significant). The presence of EBV genome into 
these patients PBMCs showed a probable potential of 
EBV in their complications although there was not any 
antibody data of specific IgM and IgG for better EBV 
comprehensions. 
EBV based on encoded its nuclear antigens (EBNAs) 
divided into two genotypes I and II. Investigations on 
different EBV genotypes shows that the EBV-I can 
promote transformation better than EBV-II in human B 
cell lines (Rickinson et al., 1987). This data suggested 
there is a possible relation between virus genotype and 
inducted disease by considering their geographical and 
epidemiological patterns. Our results showed the majority 
of EBV-II were in HL patients since it proposed to more 
complications than others. As it has been indicated in 
studies the type I is distributed all around worldwide 
while the type II is mostly limited to the Equatorial 
Africa and Southeast Asia (Chang et al., 2009; Tzellos 
and Farrell, 2012). Investigations on Asian population 
shows that they mostly infected with one type which it 
was EBV-I and only 11% of them were co-infected with 
both types I and II (Srivastava et al., 2000; Tiwawech 
et al., 2008; Zhou et al., 2001). However, Porakbary et 
al., (pourakbari et al.) by used EBNA-2 cPCR for EBV 
detection in Iranian HL and NHL patients that they 
reported EBV prevalence 41.6% and 33%, respectively. 
There is limited data about different types of EBV in 
Iranian population with hematologic malignancies. In 
the study conducted by Mahjor et al., (2010) the EBV 
IgG antibody against early antigen (EA) and EBNA-1 
were assessed in ALL patients in compare with control 
group. The study results indicated higher positive results 
for these antibodies by ELISA in ALL group. Also, in 
the study conducted by Ashraf et al., (2012) presence of 
EBV, LMP gene were investigated in diffuse large B cell 
(DLBL) patients by Immune-Histo-Chemical (IHC) and 
PCR. The results reveal 10% prevalence of LMP by PCR 
in DLBL patients. Furthermore, Habibian et al., (2013) 
showed the EBV, EBNA-1 gene presence in 48% of NHL 
patients by nested-PCR. Mean while, Jadali et al., (2008) 
indicates that 69.4% of the pediatric patients with HL had 
EBV positive results by using In situ hybridization (ISH) 
for EBER gene and IHC for LMP-1 gene in lymph nodes 
tissue. Lin et al., (1993) investigated the prevalence and 
genotypes distribution of EBV in HL patients that they 
reported 56% of them were infected with type I and 13% 
were type II. Also, they found 31% co-infection by both 
genotypes. Ai et al., (2012) studied Chinese children 
for EBV infection that they reported 98.1% EBV type 
I vs. 1.9% type II. Our result showed there was not 
any co-infection of both EBV types that it could be related 
to geographical differences and Iranian race or our study 
specific group and limited sample size although there was 
not a confirmatory test to clarify some of our probable type 
II or mixed forms. Further studies in different groups and 
broader sample size needed to better clarify the subject.
Investigations showed there are different approaches 
for EBV genotyping and differentiate this virus variants. 
EBNA-3A, -3B, 3C and EBNA-2 were used for EBV 
genotyping but the most studied and approved the method 
for determining virus into the two distinct genotypes is 
to use EBNA-3C. Regardless of differentiating virus 
based on EBNA genes into two distinct genotypes, viral 
variant classification by EBNA-1 or different regions of 
the LMP-1 gene sequence (Edwards et al., 1999; Snudden 
et al., 1995). By considering all this dividing the virus 
into two different variants based on EBNA-3C is still 
the most common method which is also clearly able to 
make difference between pathogenesis and geographical 
patterns of the virus while there is not any clear result 
about other variants of the virus yet.  
In the present study EBV infection in our population 
was detected by EBNA-2 nPCR and then EBV positive 
strains divided into two groups of genotypes I or II by 
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EBNA-3C cPCR, and EBV viral load performed by a 
qRT-PCR. Based on the collected data we showed that the 
majority of EBV positive strains were genotype I (91.2%) 
and 8.8% (3/34) were genotype II. There is no clear cause 
for EBV geographic variations in different regions but 
this could be related to host HLA polymorphisms and 
environmental factors (Chang et al., 2009; Chiara et al., 
2016). The needs to further genotype distribution studies to 
clarify their epidemiology and complications are sensible.
EBV viral load could be important for pathogenesis 
and disease prognosis especially in patients with 
malignancy. Studies on EBV viral load and its relation 
to different conditions showed the promising result. 
Smets et al., (2002) indicated that primary infection 
of EBV in PTLD (Posttransplant lymphoproliferative 
disease) patients induce high viral load and decrease 
T cell response to EBV. They concluded that the high 
viral load could indicate the risk of PTLD in patients. 
By the present study we determined the viral load of 
EBV in Lymphoproliferative disorders and hematologic 
malignancy patients via a qRT-PCR assay for EBNA-3C 
gene but limited data caused missing the status of T-cell 
in the studied population. Although we could not find 
significant results between viral load and different diseases 
or other demographic data (p>0.05), the highest viral load 
were seen in NHL patients that could be due to the broader 
sample size or their more severe malignancy compare with 
other studied patients. But it should considered that, this 
higher viral load in NHL patients were not statistically 
significance with other patients groups (p>0.05). The 
mean viral loads in our tested samples were 2.75×105 ± 
1.202×106 copies/μg DNA. A major limitation of this study 
was to the small sample size that it was due to the special 
group of our study setting by inclusion criteria. Another 
limitation was the lack of using antibody data of EBV 
specific IgM and IgG. But our study for the first time in 
Iran showed the molecular epidemiology of the EBV in 
our special population groups and there was no study about 
EBV genotyping and viral load quantitation in Iranian 
population that it needs to confirm by complementary 
further studies.
In conclusion, by the current study, we were not 
found statistically significant data for association of any 
particular hematologic malignancies and different EBV 
genotypes or viral load. We concluded nearly half (43%) 
of our population had EBV genome and 91.2% of them 
were EBV I. The mean viral load was not determine any 
particular pattern with the disease and patients conditions. 
Further studies recommended for more comprehensive 
results.
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